Didier Blaise

2 months ago | nature.com | Jaime Sanz |Myriam Labopin |Jurjen Versluis |Didier Blaise |Lorenzo Lazzari |Juan Montoro | +7 more

AbstractWe retrospectively analyzed the impact of conditioning intensity on transplant outcomes according to their cytogenetic/molecular risk in a cohort of 1823 patients with acute myeloid leukemia (AML) and intermediate- or adverse-risk cytogenetics in first complete remission (CR1). These patients received their first hematopoietic stem cell transplantation (HSCT) using post-transplant cyclophosphamide (PTCy).

Nov 11, 2024 | nature.com | Joanna Drozd-Sokolowska |František Folber |Grzegorz W. Basak |Jane F. Apperley |Alessandro Rambaldi |Marek Trneny | +6 more

AbstractAutologous hematopoietic cell transplants (auto-HCTs) remain the standard of care for transplant-eligible MM patients. The general practice has been to undergo upfront apheresis following induction to collect sufficient number of CD34+ cells to facilitate two auto-HCTs. However, 5–30% of MM patients do not initially mobilise a sufficient number of hematopoietic stem cells and are classified as poor mobilizers (PM).

Aug 1, 2024 | nature.com | Myriam Labopin |Depei Wu |Mahmoud Aljurf |Edouard Forcade |Jakob Passweg |Thomas Pabst | +7 more

AbstractCore-binding factor acute myeloid leukemia (CBF-AML) represents 12–15% of all AML cases. Although CBF positivity infers a survival advantage, overall survival (OS) remains dismal. Treatment is with cytarabine/anthracycline-based chemotherapy induction followed by high-dose cytarabine (HiDAC) consolidation. Allogeneic hematopoietic stem cell transplantation (allo-SCT) is reserved for relapse or for patients having not achieved MRD-negativity at high risk for relapse.

Jul 26, 2024 | nature.com | Didier Blaise

To the editor,Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative therapy for hematological malignancies; graft-versus-host disease (GvHD) is one of the major barriers to successful transplantation. Post-transplant cyclophosphamide (PTCy), a widely used strategy for GvHD prophylaxis, considerably lowers the incidence of fatal GvHD [1].

Jul 23, 2024 | chi.scholasticahq.com | Finn Petersen |Mohamad Mohty |Didier Blaise

As senior hematologists and cell therapists with more than 100 years of experience in this area between us, we receive many letters and e-mails from patients. Some of these graciously thank us and the staff for excellent care, and some are complaints about “something that went wrong” in their care experience.